Personalised blueprint intestinal health

The miGut-Health consortium aims to develop a personalized blueprint of intestinal health to predict and prevent inflammatory bowel disease.

The overall goal is to deliver interdisciplinary solutions (molecular, nutritional, eHealth and patient engagement/empowerment level) for health promotion and disease prevention that would enable active patient engagement in health and self-care management.

Taking on this mission, miGut-Health pursues the following strategic goals:- To integrate state-of-the-art omics (molecular, clinical, nutrition, social and environmental) for identification of actionable biomarkers, risk and health promoting factors linked to health-to-disease transition in the general population, IBD high risk persons, as well as IBD patients.- To perform systems-level analyses of chronic inflammation by applying integrative models from omics and clinical data to predict risk for health-to-disease transition in IBD.- To perform a proof-of-concept controlled clinical trial studying a nutrient elimination diet (here: gluten-free diet) and its impact on intestinal inflammation in IBD patients and high-risk individuals.- To exploit the impact of microbiome-derived diet-associated metabolites on gut inflammation reversion and restoration of barrier integrity and function using an innovative co-culture system of primary human intestinal organoids and sorted immune cell subsets.- To develop and apply novel technologies (sensors, mobile apps) to dynamically monitor individual nutrition as well as physical activity and principal health status.- To implement a patient-centered approach for personalized health and self-care engagement targeted at IBD patients, individuals at risk for IBD and the general population as well as tools for health-care professionals.